What is Fibroblast?
Fibroblast operates as a specialized referral management platform designed to rectify the fragmented nature of patient transitions between healthcare providers. By deploying end-to-end digital tools, the platform empowers medical organizations to actively manage the referral lifecycle, effectively closing the loop on patient care. This technological intervention is essential for mitigating patient leakage, a persistent challenge that undermines revenue stability for fee-for-service organizations. Furthermore, by streamlining these complex administrative processes, Fibroblast provides accountable care organizations with the necessary infrastructure to lower operational risks and demonstrate a clear, measurable return on investment in a value-based care environment.
How much funding has Fibroblast raised?
Fibroblast has raised a total of $2.9M across 3 funding rounds:
Private Equity
$727K
Private Equity
$2M
Debt
$150K
Private Equity (2013): $727K, investors not publicly disclosed
Private Equity (2018): $2M, investors not publicly disclosed
Debt (2020): $150K supported by PPP
Key Investors in Fibroblast
Undisclosed Investor
An institutional capital provider focused on long-term growth and operational scaling within the healthcare technology sector.
PPP
Public-Private Partnership
Undisclosed Investor
A strategic investment partner specializing in the development of high-impact digital health infrastructure.
What's next for Fibroblast?
With the recent capital deployment, Fibroblast is well-positioned to accelerate its market penetration and enhance its suite of provider-centric tools. The focus will likely shift toward deepening integration capabilities with existing electronic health record systems to ensure seamless data interoperability. As the healthcare industry continues to prioritize patient retention and care coordination, Fibroblast's strategic roadmap will likely emphasize the expansion of its analytics engine to provide deeper insights into referral patterns and network performance. By leveraging this recent financing, the company aims to solidify its status as an indispensable partner for health systems striving to optimize their referral networks and improve overall clinical outcomes.
See full Fibroblast company page
